Tilak Kumar Sundaresan, M.D.
Hematology & Oncology Physician · Boston, MA
Tilak Kumar Sundaresan, M.D. is a hematology & oncology physician with a practice address in Boston, Massachusetts, and NPI 1114252707, issued on Oct 15, 2009. Check the license (Massachusetts 247203, as entered in NPPES) on the Massachusetts Board of Registration in Medicine; the Medicare figures below come from public CMS files.
- Name
- Tilak Kumar Sundaresan
- Credential
- M.D.
- Primary taxonomy
- Hematology & Oncology Physician 207RH0003X
- License number
- 247203 MA
Self-reported in NPPES; status is on the state search - Practice location
- 55 Fruit St, Boston, MA 02114
- Phone
- (617) 724-4000
- Enumerated
- Oct 15, 2009
- Record last updated
- Feb 11, 2022
- Medicare enrollment
- Enrolled (PECOS I20170505000281); accepts Medicare assignment
- Medical or professional school
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc), 2008
- Entity
- Type 1 · individual
8 nearest hematology & oncology physician records → All 461 in Massachusetts → Look up another NPI →
Also registered at 55 Fruit St
A shared address usually means a shared clinic or building; it does not show who employs whom.
- Affan Aamir, MD, PHARMD, RPHStudent in an Organized Health Care Education/Training Program1821890377
- Matthew AbadirAnesthesiology Physician1699120550
- Taimur AbbasiInternal Medicine Physician1841673522
- Megan Abbott, MDAnesthesiology Physician1730839333
- Moustafa AbdallaStudent in an Organized Health Care Education/Training Program1952046062
- Shadi Abdar Esfahani, MD, MPHDiagnostic Radiology Physician1497137590
Verify Tilak Kumar Sundaresan in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersMassachusetts Board of Registration in Medicine
Search for license 247203Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
85% fewer Medicare Part D claims than the average hematology & oncology physician in 2024
135 Medicare Part D claims for 42 beneficiaries, against an average of 877 among the 10,784 providers of this specialty who prescribed in Part D. Brand-name drugs were 26% of claims.
Most prescribed
- Zenpep18 claims
- Ondansetron Hcl16 claims
- Dexamethasone14 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
Bills Medicare through one group practice
- Permanente Medical Group IncSan Francisco, CA
Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).
Tilak Kumar Sundaresan among 461 hematology & oncology physician records in Massachusetts
Tilak Kumar Sundaresan, M.D. is one of 461 hematology & oncology physician records with a practice address in Massachusetts. 75% of them appear in a Medicare file (Part D prescribing, MIPS, Open Payments or Medicare group billing); this one does. Its NPI, issued in 2009, is newer than 66% of them.
- NPI issued2009 · 66% of these records are older, 30% newer
- In a Medicare fileYes · 75% of these records are
- In the CMS Doctors and Clinicians fileYes · 66% of these records are
- Graduated2008 · median 2004 among the 303 with a school on file
- Record last updated2022 · 62% of these records were not updated in five years or more
Source: CMS NPPES, file of Aug 9, 2026, every record with primary taxonomy 207RH0003X and a Massachusetts practice address; Medicare files: CMS Part D Prescribers 2024, MIPS 2023, Open Payments 2024, Doctors and Clinicians (data.cms.gov).
Hematology & Oncology Physician providers in Massachusetts
There are 461 hematology & oncology physician records in Massachusetts.
All 461 in Massachusetts → Every provider in Boston → Hematology & Oncology Physician nationwide →
The 8 hematology & oncology physician records with the nearest ZIP codes
- Vassiliki Boussiotis, MD PHDBoston, MA 021141861474215
- Marcia Browne, MDBoston, MA 021141639146210
- George Canellos, MDBoston, MA 021141114908027
- Yi-Bin Chen, MDBoston, MA 021141356332639
- John ClarkBoston, MA 021141871550244
- Lauren Dias, MDBoston, MA 021141215928346
- Kira Gritsman, MDBoston, MA 021141174598148
- David HarmonBoston, MA 021141851358352
Common questions
What is Tilak Kumar Sundaresan, M.D.'s NPI number?
Tilak Kumar Sundaresan, M.D.'s National Provider Identifier (NPI) is 1114252707, issued on Oct 15, 2009. An NPI identifies a provider in billing; it is not a license.
Where is Tilak Kumar Sundaresan, M.D. located?
The NPPES record lists a practice address at 55 Fruit St, Boston, MA, 02114. Phone: (617) 724-4000. Providers update this record themselves, so call before visiting.
How can I verify Tilak Kumar Sundaresan, M.D.'s license?
NPPES lists Massachusetts license number 247203, as entered by the provider. Search the Massachusetts Board of Registration in Medicine at https://findmydoctor.mass.gov/. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.
How much does Tilak Kumar Sundaresan, M.D. prescribe under Medicare Part D?
In 2024, Tilak Kumar Sundaresan, M.D. had 135 Medicare Part D claims for 42 beneficiaries; the average among hematology & oncology physician prescribers was 877. Part D covers Medicare prescriptions only.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.